SCHEMBL22490890

SCHEMBL22490890

COc1cc(C(=O)O)cc(Cl)c1OCc1cccc(OC(C)(C)C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 13/20 0.50
KDM4E B2RXH2 1/20 0.47
PTPN2 P17706 1/20 0.47
PTPN1 P18031 1/20 0.47
ACP1 P24666 1/20 0.47
TP53 P04637 2/20 0.46
NFKB1 P19838 2/20 0.46
RAB9A P51151 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PKM P14618 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
PTPN7 P35236 1/20 0.45
PTPN12 Q05209 1/20 0.45
PTPN22 Q9Y2R2 1/20 0.45
NR4A2 P43354 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
MITF O75030 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10323084 0.84 KDM4E (0.64) MRGPRX4KDM4EPTPN2PTPN1ACP1
SCHEMBL27955353 0.81 MRGPRX4 (0.65) MRGPRX4TP53NFKB1RAB9ANFKB2
SCHEMBL12433003 0.78 RXRA (0.61) MRGPRX4NR4A2MEN1XBP1KMT2A
SCHEMBL23488588 0.77 LGALS3 (0.40) PTPN1
SCHEMBL22490887 0.76 ALDH1A1 (0.35) KDM4EPTPN2PTPN1ACP1
SCHEMBL23488537 0.76 CA2 (0.44)
SCHEMBL10323322 0.76 KDM4E (0.62) MRGPRX4KDM4EPTPN2PTPN1ACP1
SCHEMBL22490884 0.76 LGALS8 (0.35) MRGPRX4KDM4EPTPN2PTPN1ACP1
SCHEMBL2317454 0.75 RXRA (0.61) MRGPRX4RAB9ASMN1; SMN2MEN1NPC1
SCHEMBL9356045 0.75 RAB9A (0.58) MRGPRX4KDM4ETP53NFKB1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed
EP-3717463-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2020-10-07 EP disclosed
CN-111433193-A Novel conjugates of agents and moieties capable of binding to glucose sensing proteins 赛诺菲 2020-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MRGPRX4 87/4885KDM4E 4293/4885PTPN2 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.